Comparison
DSIP vs. GHRP-2
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
62568-57-4
158861-67-7
Molecular weight
848.81 g/mol
817.93 g/mol
Half-life
0.1 h
0.5 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluD-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
1
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1